Alcohol use disorders (AUDs) are among the most prevalent psychiatric disorders. Epidemiologic studies have shown a high prevalence of concurrent psychiatric disorders among people with AUDs as well as a higher prevalence of AUDs in people with psychiatric disorders than in the general population. Though psychiatric patients with concurrent AUDs are at increased risk for morbidity and mortality, they are commonly undertreated for their alcohol-related disorders. The efficacy of pharmacotherapy for AUDs is well documented. Our paper reviews the common pharmacotherapies available for AUDs and focuses on the available research regarding treatment of AUDs among psychiatric populations with mood, anxiety, and psychotic disorders. Despite the high prevalence of concurrent AUDs and psychiatric disorders, very limited information has been collected using a randomized controlled trial design targeting those concurrent conditions. Several prevalent psychiatric disorders have not been studied when co-occurring with AUDs. Further research of pharmacological treatments for concurrent AUDs and psychiatric diagnoses is urgently needed.
GrantBStinsonFDawsonD, Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–816.
2.
KesslerRCCrumRMWarnerLA, Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313–321.
3.
RegierDAFarmerMERaeDS, Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–2518.
4.
FarrellMHowesSBebbingtonP, Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey. Br J Psychiatry. 2001;179:432–437.
5.
HasinDSStinsonFSOgburnE, Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64:830–842.
6.
DixonL.Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res. 1999;35 Suppl:S93–S100.
7.
HasinDGoodwinRStinsonF, Epidemiology of major depressive disorder: Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62:1097–1106.
8.
KesslerRCNelsonCBMcGonagleKA, Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;(30):17–30.
9.
RushBUrbanoskiKBassaniD, Prevalence of co-occurring substance use and other mental disorders in the Canadian population. Can J Psychiatry. 2008;53:800–809.
10.
GalanterMCastanedaRFermanJ.Substance abuse among general psychiatric patients: Place of presentation, diagnosis, and treatment. Am J Drug Alcohol Abuse. 1988;14:211–235.
11.
RushBKoeglCJ. Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system. Can J Psychiatry. 2008;53:810–821.
12.
BroonerRKKingVLKidorfM, Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71–80.
13.
HienDZimbergSWeismanS, Dual diagnosis subtypes in urban substance abuse and mental health clinics. Psychiatr Serv. 1997;48:1058–1063.
14.
CorneliusJRBuksteinOSalloumI, Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003;16:361–374.
15.
CorneliusJRSalloumIMMezzichJ, Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry. 1995;152:358–364.
16.
KranzlerHRRosenthalRN. Dual diagnosis: Alcoholism and co-morbid psychiatric disorders. Am J Addict. 2003;12(Suppl 1):S26–S40.
17.
MueserKTDrakeREWallachMA. Dual diagnosis: A review of etiological theories. Addict Behav. 1998;23:717–734.
18.
WoodyG.The challenge of dual diagnosis. Alcohol Res Health. 1996;20:76–80.
19.
GoldsteinBIDiamantourosASchafferA, Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs. 2006;66:1229–1237.
20.
Health Canada; RushB, principal author. Best practice for concurrent mental health and substance use disorders. Ottawa (ON): Health Canada; 2001. Catalogue number: H39–599/2001–2E. ISBN: 0-662-31388-7.
21.
SchuckitMATippJEAnthenelliRM, Anorexia nervosa and bulimia nervosa in alcohol-dependent men and women and their relatives. Am J Psychiatry. 1996;153:74–82.
22.
MurphyGE. Suicide in alcoholism. New York (NY): Oxford University Press; 1992.
23.
VerheulRKranzlerHRPolingJ, Axis I and Axis II disorders in alcoholics and drug addicts: Fact or artifact?J Stud Alcohol. 2000;61:101–110.
24.
LaBountyLPHatsukamiDMorganSF, Relapse among alcoholics with phobic and panic symptoms. Addict Behav. 1992;17:9–15.
25.
PickensRWHatsukamiDKSpicerJW, Relapse by alcohol abusers. Alcohol Clin Exp Res. 1985;9:244–247.
26.
SvanumSMcAdooWG. Predicting rapid relapse following treatment for chemical dependence: A matched-subjects design. J Consult Clin Psychol. 1989;57:222–226.
27.
HodginsDCel-GuebalyNArmstrongS.Prospective and retrospective reports of mood states before relapse to substance use. J Consult Clin Psychol. 1995;63:400–407.
28.
DrakeREMercer-McFaddenCMueserKT, Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24:589–608.
29.
SuhJJPettinatiHMKampmanKM, The status of disulfram: A half of a century later. J Clin Psychopharmacol. 2006;26:290–302.
30.
O'BrienCPVolpicelliLAVolpicelliJR. Naltrexone in the treatment of alcoholism: A clinical review. Alcohol. 1996;13:35–39.
31.
O'MalleySSJaffeAJChangG, Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881–887.
32.
VolpicelliJRAltermanAIHayashidaM, Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880.
33.
SrisurapanontMJarusuraisinN.Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005;(1):CD001867.
34.
AntonRF. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008;9:655–658.
35.
OslinDWBerrettiniWKranzlerHR, A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546–1552.
36.
RösnerSHackl-HerrwerthALeuchtS, Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9):CD004332.
37.
HammarbergAJayaram-LindströmNBeckO, The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: A randomized controlled trial. Psychopharmacology (Berl). 2009;205:53–62.
38.
JohnsonBAAit-DaoudNAkhtarFZ, Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: A randomized controlled trial. Arch Gen Psychiatry. 2004;61:905–912.
39.
JohnsonBAAit-DaoudNBowdenCL, Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet. 2003;361:1677–1685.
40.
JohnsonBARosenthalNCapeceJA, Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA. 2007;298:1641–1651.
41.
GarbuttJCKampov-PolevoyABGallopR, Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34:1849–1857.
42.
AddoloratoGCaputoFCapristoE, Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504–508.
43.
PetrakisILNichCRalevskiE.Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32:644–654.
44.
GreenAIDrakeREBrunetteMF, Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007;164:402–408.
45.
DrakeREXieHMcHugoGJ, The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441–449.
46.
SoykaMAichmullerCv BardelebenU, Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: Results from an open clinical study. Eur Addict Res. 2003;9:65–72.
47.
MueserKTNoordsyDLFoxL, Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003;12:242–252.
48.
PetrakisILO'MalleySRounsavilleB, Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl). 2004;172:291–297.
49.
TekCSrihariVTekE.Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr Res. 2008;106(2–3):373.
50.
KalyoncuAMirsalHPektasO, Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: A potent anti-craving effect?J Psychopharmacol. 2005;19:301–305.
51.
WeismanRL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: A case report. Int J Psychiatry Med. 2003;33:85–89.
52.
MasonBJKocsisJHRitvoEC, A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275:761–767.
53.
McGrathPJNunesEVStewartJW, Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53:232–240.
54.
CorneliusJRSalloumIMEhlerJG, Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700–705.
55.
RoyA.Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998;44:633–637.
56.
GualABalcellsMTorresM, Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: A randomized controlled trial. Alcohol Alcohol. 2003;38:619–625.
57.
MoakDHAntonRFLathamPK, Sertraline and cognitive behavioral therapy for depressed alcoholics: Results of a placebo-controlled trial. J Clin Psychopharmacol. 2003;23:553–562.
58.
Roy-ByrnePPPagesKPRussoJE, Nefazodone treatment of major depression in alcohol-dependent patients: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20:129–136.
59.
Hernandez-AvilaCAModesto-LoweVFeinnR, Nefazodone treatment of comorbid alcohol dependence and major depression. Alcohol Clin Exp Res. 2004;28:433–440.
60.
PettinatiHM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56:785–792.
61.
NunesEVLevinFR. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA. 2004;291:1887–1896.
62.
TorrensMFonsecaFMateuG, Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78:1–22.
63.
PetrakisIRalevskiENichC, Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27:160–165.
64.
SalloumIMCorneliusJRThaseME, Naltrexone utility in depressed alcoholics. Psychopharmacol Bull. 1998;34:111–115.
65.
LejoyeuxMLehertP.Alcohol-use disorders and depression: Results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol. 2011;46:61–67.
66.
PettinatiHMOslinDWKampmanKM, A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167:668–675.
67.
FryeMASalloumIM. Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations. Bipolar Disord. 2006;8:677–685.
68.
SalloumIMCorneliusJRDaleyDC, Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37–45.
69.
BrownESCarmodyTJSchmitzJM, A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33:1863–1869.
70.
KranzlerHRBurlesonJADel BocaFK, Buspirone treatment of anxious alcoholics: A placebo-controlled trial. Arch Gen Psychiatry. 1994;51:720–731.
71.
TollefsonGDMontague-ClouseJTollefsonSL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol. 1992;12:19–26.
72.
MalcolmRAntonRFRandallCL, A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992;16:1007–1013.
73.
BradyKTSonneSAntonRF, Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005;29:395–401.
74.
PetrakisILPolingJLevinsonC, Naltrexone and disulfram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry. 2006;60:777–783.
75.
ThomasSERandallPKBookSW, A complex relationship between co-occurring social anxiety and alcohol use disorders: What effect does treating social anxiety have on drinking?Alcohol Clin Exp Res. 2008;32:77–84.
76.
RandallCLJohnsonMRThevosAK, Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14:255–262.
77.
DierksMRJordanJKSheehanAH. Prazosin treatment of nightmares related to posttraumatic stress disorder. Ann Pharmacother. 2007;41:1013–1017.
78.
SimpsonTLSaxonAJMeredithCW, A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009;33:255–263.
